摘要
目的探讨利拉鲁肽联合唑来膦酸、碳酸钙D_(3)治疗糖尿病性骨质疏松症的效果及对骨保护蛋白(OPG)、Apelin-13的影响。方法选取2020年1月至2022年3月收治的150例糖尿病性骨质疏松症患者为研究对象,按照随机数字表法将其分为对照组与观察组,各75例。对照组采用唑来膦酸、碳酸钙D_(3)治疗,观察组在对照组基础上给予利拉鲁肽治疗。比较两组的治疗效果、OPG、Apelin-13水平、糖代谢及骨代谢指标。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,观察组的OPG、Apelin-13水平高于对照组(P<0.05)。治疗后,观察组的糖化血红蛋白(HbA1c)、空腹血糖(FPG)、空腹胰岛素(FINS)水平低于对照组(P<0.05)。治疗后,观察组的骨源性碱性磷酸酶(BALP)、分泌型卷曲相关蛋白5(SFRP5)水平高于对照组,β-Ⅰ型胶原羧基端肽(β-CTX)水平低于对照组(P<0.05)。结论利拉鲁肽联合唑来膦酸、碳酸钙D_(3)治疗糖尿病性骨质疏松症可提高临床效果,改善糖代谢及骨代谢指标,调节OPG、Apelin-13水平。
Objective To investigate the effect of liraglutide combined with zoledronic acid and calcium carbonate D_(3) in the treatment of diabetic osteoporosis and its influences on osteoprotegerin(OPG)and Apelin-13.Methods A total of 150 patients with diabetic osteoporosis admitted from January 2020 to March 2022 were selected as the research objects.According to the random number table method,the patients were divided into control group and observation group,with 75 cases in each group.The control group was treated with zoledronic acid and calcium carbonate D_(3),and the observation group was treated with liraglutide on the basis of the control group.The therapeutic effect,OPG,Apelin-13 levels,glucose metabolism and bone metabolism indexes were compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the levels of OPG and Apelin-13 in the observation group were higher than those in the control group(P<0.05).After treatment,the levels of glycosylated hemoglobin(HbA1c),fasting plasma glucose(FPG)and fasting insulin(FINS)in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of bone alkaline phosphatase(BALP)and secreted frizzled-related protein 5(SFRP5)in the observation group were higher than those in the control group,and the level ofβ-C-terminal telopeptide of typeⅠcollagen(β-CTX)was lower than that in the control group(P<0.05).Conclusion Liraglutide combined with zoledronic acid and calcium carbonate D_(3) in the treatment of diabetic osteoporosis can elevate the clinical effect,improve the indexes of glucose metabolism and bone metabolism,and regulate the levels of OPG and Apelin-13.
作者
林园园
马医林
雷烨
LIN Yuanyuan;MA Yilin;LEI Ye(Hanzhong People's Hospital,Hanzhong 723000;the Second Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712000,China)
出处
《临床医学研究与实践》
2024年第21期33-36,共4页
Clinical Research and Practice
基金
2020年陕西中医药大学第二附属医院学科创新团队项目(No.2020XKTD-C01)。
